Ranked #3,090 of 8,699 institutional investors
Johnson & Johnson
New Brunswick, NJ
$657M
US stock portfolio at live prices · today −$6.9M (−1.05%)
Market closed. Prices as of Nov 20, 5:41 AM ET
- Value at quarter end (Q3 2026)
- $762M
- Change from Q2 2026
- −$37.0M (−4.63%)
- Positions
- 14 · 0 new, 0 sold out
- Filed
- Oct 26, 2026
Not counted in the ranking: none$73.1M of holdings we could not match to a US listing are included at their reported quarter-end value.
Holdings
Q3 2026 13F, live pricesPTGX 46.2%NBTX 23.4%RAPP 6.41%XNCR 3.87%CTNM 2.72%
| Stock | Shares | Value, live | % of portfolio | vs Q2 2026 |
|---|---|---|---|---|
| PTGX Protagonist Therapeutics, Inc. | 2,449,183 | $304M | 46.2% | Unchanged |
| NBTX Nanobiotix S.A. | 5,623,816 | $154M | 23.4% | Unchanged |
| RAPP Rapport Therapeutics, Inc. | 1,784,517 | $42.1M | 6.41% | Unchanged |
| XNCR Xencor, Inc. | 748,062 | $25.4M | 3.87% | Unchanged |
| CTNM Contineum Therapeutics, Inc. | 1,979,173 | $17.9M | 2.72% | Unchanged |
| LEGN Legend Biotech Corporation | 814,586 | $13.1M | 2.00% | Unchanged |
| CBRS Cerebras Systems Inc. | 128,649 | $11.2M | 1.70% | Added +140% |
| PRCT PROCEPT BioRobotics Corporation | 357,939 | $9.2M | 1.40% | Unchanged |
| FATE Fate Therapeutics, Inc. | 3,379,064 | $3.4M | 0.52% | Unchanged |
| CVRX CVRx, Inc. | 4,024,861 | $2.1M | 0.33% | Unchanged |
| VOR Vor Biopharma Inc. | 53,732 | $995K | 0.15% | Unchanged |
| NMRA Neumora Therapeutics, Inc. | 1,849,445 | $642K | <0.1% | Unchanged |
| LAB Standard BioTools Inc. | 311,967 | $192K | <0.1% | Unchanged |
| ACET Adicet Bio, Inc. | 22,779 | $56K | <0.1% | Unchanged |